China Pharma Holdings, Inc. — Q3 2019 Form 10-Q
Business context and reporting period. The company manufactures and markets generic, branded and biochemical pharmaceutical products in China, primarily selling to hospitals and private retailers. This unaudited report covers the three and nine months ended September 30, 2019; comparisons are to the same 2018 periods unless noted. Financial amounts below are in U.S. dollars.
Financial results and liquidity
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $2.38 million | $2.30 million | $7.88 million | $9.09 million |
| Gross profit / margin | $0.37 million / 15.7% | $0.51 million / 22.3% | $1.19 million / about 15% | $2.15 million / about 24% |
| Operating loss | $0.65 million | $1.93 million | $1.73 million | $2.94 million |
| Net loss | $0.70 million | $1.86 million | $1.96 million | $3.16 million |
| Loss per share, basic and diluted | $0.02 | $0.04 | $0.04 | $0.07 |
- Cash flow: Nine-month operating cash flow was $1.40 million, investing cash outflow was $0.09 million, and financing cash outflow was $1.72 million. Cash and cash equivalents fell by $0.42 million to $0.76 million; restricted cash was $0.49 million.
- Balance sheet and debt: At September 30, current assets were $6.24 million and current liabilities were $9.61 million. Total liabilities were $12.54 million. The construction loan had $4.24 million outstanding, including $2.12 million current, with the next scheduled principal payments in 2020 and 2021. Bankers’ acceptance notes payable were $0.49 million and were collateralized by restricted cash.
- Receivables and inventory: Net trade receivables were $0.69 million, against a $17.36 million allowance; inventory was $3.97 million. The company reported that 95.6% of receivables were more than 720 days old.
Material changes and management commentary
- Q3 revenue increased 3.4%, but cost of revenue rose to 84% of sales and gross margin fell to 15.7%, primarily because fixed costs weighed more heavily on revenue. CNS and cardiovascular sales increased; digestive and other-category sales declined.
- Nine-month revenue declined 13.3%. Lower sales of anti-viral/infection and respiratory products, Vitamin B6 and digestive products were attributed mainly to market fluctuations. Cost of revenue declined in dollars but increased as a share of sales; gross profit fell to $1.19 million.
- Net losses improved in both comparison periods, principally reflecting much lower bad-debt expense than in 2018 and, for Q3, expenditure controls. The improvement does not reflect stronger year-to-date revenue or gross margin.
- Management cited stricter drug registration and generic-drug consistency evaluation requirements, higher clinical-trial and environmental-compliance costs, and shortages of active pharmaceutical ingredients and intermediates. Approval timelines for pipeline products have lengthened; the company said certain product development was terminated and there was no further pipeline progress in Q3.
Outlook, risks and unusual items
- Going concern: The filing states that substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements. Management expects operating losses to continue. It plans to promote customer prepayments, improve collections, explore strategic alternatives to accelerate nutrition products, and consider using fixed assets as collateral for additional borrowing. These plans were not finalized or sufficiently within management’s control to alleviate the substantial doubt under the stated accounting assessment.
- Management said its operating plan was expected to fund working capital and anticipated capital spending for the next 12 months, but also warned that additional financing might be needed and may not be available on acceptable terms. The company relied on advances and a $674,405 loan from its chairperson, CEO and interim CFO; the loan bears 4.35% interest and is due within one year.
- All revenue is denominated in RMB; currency conversion and remittances from China are subject to government controls. The company also cited PRC political, regulatory and economic risks, and exposure to changing interest rates.
- Two customers represented 49.5% and 10.7% of accounts receivable; two suppliers accounted for 21.7% and 19.3% of raw-material purchases. The filing also discloses approximately $0.30 million of future payments tied to phases of formula-approval contracts.
- Disclosure controls were deemed ineffective because of a material weakness involving a lack of personnel knowledgeable in U.S. GAAP financial reporting. Management nevertheless stated that the presented financial statements were fairly stated in all material respects.
Important facts for investors to verify
- Whether the company can meet near-term obligations, including the $2.12 million current construction-loan portion and the related-party loan due within one year, without dependable new financing.
- Collection prospects and the recoverability assumptions for the heavily aged receivables, including the large allowance and customer concentration.
- Whether management’s proposed liquidity and strategic plans become finalized and executable, given the explicit going-concern substantial doubt.
- Whether drug-approval delays, consistency-evaluation requirements, input-cost pressures and declining year-to-date sales continue to constrain margins and product development.
- Progress in remediating the disclosed material weakness in U.S. GAAP financial reporting controls.